In early 2020, we all became aware of a new pandemic, COVID-19.
It quickly became apparent that in some patients the virus was associated with a severe coagulopathy, resulting in significant morbidity and mortality.
Emerging evidence has indicated that coagulation changes play a major role in the pathophysiology of COVID, particularly Long-COVID, the persistent symptoms following infection.
In this presentation, Dr. Resia Pretorius discusses use of cutting edge laboratory studies in coagulation and vascular biology, as it applies to COVID.
Etheresia Pretorius PhD
Stellenbosch University, South Africa
resiap@sun.ac.za
At the completion of this presentation, the learner will be familiar with (1) the concept of amyloid fibril formation, as an alternative structure of fibrinogen, and (2) its role in Long Covid and other pathologic states.
Disclosures for Etheresia Pretorius PhD
Funding and Other Disclosures:
Polybio Research Foundation (USA),
Balvi Research Foundation
Kanro Research Foundation
KERNLS crowd funding initiative, together with patients and their family members, clinicians and researchers
StandingUpToPOTS (USA)
MRC and NRF (South Africa),
Disclosure Founding Director of Biocode Technologies
